The wider net loss and cash burn of $57.4M in operating cash flow are offset by the $1.18B pro forma cash position and positive pipeline catalysts. Key catalysts to watch: SPY002 and SPY003 topline data in mid-2026 and Q3 2026, RA sub-study readout in Q3 2026, and combination data in 2027. The $463M offering closed in April 2026 removes near-term dilution risk but the stock may trade on pipeline data rather than financials.
SYRE drugs
SYRE drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 5 $71.01entry
- T+1 · 7mo ago +2.80%α +1.42% · $73.00
- T+5 · 6mo ago +7.63%α +5.65% · $76.43
- T+20 · 6mo ago −2.61%α −7.56% · $69.16
- T+60 · 4mo ago +42.94%α +40.20% · $101.50
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Spyre Therapeutics reported Q1 2026 financial results with a net loss of $69.0M ($0.74 per share), wider than the $44.8M loss in Q1 2025, driven by higher R&D and G&A expenses and a $30.4M non-cash charge from CVR fair value changes. The company highlighted positive Phase 2 data for SPY001 in ulcerative colitis, over-enrollment of the RA sub-study, and a pro forma cash position of $1.18B following a $463M public offering, providing runway into H2 2029. The wider loss and lack of revenue (pre-revenue biotech) make this a neutral-to-bearish financial report, but the strong pipeline progress and extended cash runway are positive offsets.
Key Financial Metrics
Key Facts
- Net loss of $69.0M in Q1 2026 vs $44.8M in Q1 2025, driven by higher R&D ($60.4M vs $41.6M) and G&A ($15.2M vs $11.9M) expenses
- Pro forma cash of $1.18B as of March 31, 2026, including $435.3M net proceeds from April 2026 public offering, providing runway into H2 2029
- Positive topline Phase 2 data for SPY001 in ulcerative colitis: 40% clinical remission, 51% endoscopic improvement, statistically significant RHI reduction
- RA sub-study of SKYWAY Phase 2 trial over-enrolled, topline readout accelerated to Q3 2026
- Net cash used in operating activities was $57.4M for Q1 2026
- Recognized $30.0M gain on sale of legacy Aeglea asset pegzilarginase upon FDA approval
- CVR liability increased to $56.95M from $26.68M at year-end 2025, driving $30.4M other expense
Financial Impact
Net loss widened by $24.2M YoY to $69.0M; no revenue reported (pre-revenue biotech)
Risk Factors
- Widening net loss and increasing R&D spend ($60.4M in Q1) could pressure cash runway if pipeline milestones are delayed
- CVR liability of $56.95M creates potential future cash outflow of ~$23M in Q2 2026
- Clinical-stage biotech with no approved products or revenue, all value depends on clinical trial outcomes
- Recent $463M offering dilutes existing shareholders; 78.8M shares outstanding vs 60.3M a year ago
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001636282-26-000051 |
| Document: syre-20260505.htm | 0001636282-26-000051 |
| Document: 0001636282-26-000051-index-headers.html | 0001636282-26-000051 |
| Document: 0001636282-26-000051-index.html | 0001636282-26-000051 |
| Document: 0001636282-26-000051.txt | 0001636282-26-000051 |
| 8-K Data (Synthetic) | 0001636282-26-000051 |
Track record
36 reports on SYRE
8 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +54.27% at T+60 after the Apr 13, 2026 report. 15 of 21 went positive at some point.
Filters
- Nov 3, 202613d ago 8-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Bearish 5/10 Entry $99.04 Now $99.37 −0.33% settles Feb 2
- Oct 12, 20265w ago Institutional Cluster Bullish 4/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
- Oct 9, 20265w ago SC 13D/A Neutral 3/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
- Oct 7, 20265w ago 8-K Bearish 5/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
- Oct 6, 20265w ago 424B5 Bearish 6/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
- Oct 5, 20266w ago Press Release Bearish 6/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 5, 20266w ago 424B5 Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 5, 20266w ago Press Release Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 2, 20266w ago Insider Cluster Bearish 4/10 Entry $92.72 Now $99.37 −7.17% settles Dec 30
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers